Berhyanda Limited, the promoter of Cohance Lifesciences , has declared that it has not created any encumbrance on the company's shares during the financial year 2025-26, other than those already disclosed. The declaration was submitted to the stock exchanges on April 7, 2026, under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

The disclosure confirms that Berhyanda Limited, along with persons acting in concert (PACs) such as Jusmiral Holdings Limited, Berhyanda Midco Limited, and Jusmiral Midco Limited, has not directly or indirectly encumbered any shares beyond what was previously reported. The filing was addressed to the BSE and NSE for their information and records.

Key Details of the Disclosure

The following table outlines the entities involved in the declaration:

The letter was signed by Christodoulos Patsalides, Director of Berhyanda Limited. A copy of the declaration has also been forwarded to the Audit Committee of Cohance Lifesciences.

Promoters of Cohance Lifesciences Limited have pledged 207.97 million equity shares, representing 54.36% of the total share capital, to secure term loan facilities availed from a consortium of lenders. The pledge was created in favour of Catalyst Trusteeship Limited, acting as the onshore security agent, on June 17, 2026. This encumbrance covers the cumulative shareholding of Berhyanda Limited and Jusmiral Holdings Limited, the promoter entities.

The disclosure was made under Regulation 29(1) read with Regulation 29(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The borrowing entities entered into a facility agreement dated June 11, 2026, with lenders including Barclays Bank Plc, Deutsche Bank AG, Singapore Branch, BNP PARIBAS, MUFG Bank, Ltd. Singapore Branch, and Standard Chartered Bank (Singapore) Limited.

Details of Pledge and Encumbrance

The first-ranking exclusive pledge secures facilities under the facility agreement. The specific shares pledged include 127.54 million shares (33.34% of total capital) held by Berhyanda Limited and 80.43 million shares (21.02% of total capital) held by Jusmiral Holdings Limited. The total voting capital of the target company stands at 382.57 million shares.

Covenants and Restrictions

Alongside the pledge, the promoters agreed to covenants effective June 16, 2026, which act as encumbrances over a larger holding of 219.93 million shares, or 57.49% of the total share capital. These covenants impose restrictions on the disposal of shares and the creation of any further security on the shareholding. The extended encumbrance covers the entire promoter holding, including 92.39 million shares (24.15%) held by Jusmiral Holdings Limited that are not part of the immediate pledge.

Furthermore, 100% of the shares held by the shareholders of the borrowing entities have been pledged in favour of CSCGlobal Capital Markets (Singapore) Pte. Ltd., the offshore security agent. This offshore pledge became effective on June 16, 2026. However, the shareholders of the borrowers have not created any direct encumbrance over the equity shares of Cohance Lifesciences Limited.